CureDuchenne Ventures

CureDuchenne Ventures is the investment arm of CureDuchenne, a nonprofit organization dedicated to curing Duchenne muscular dystrophy (DMD). The firm focuses on funding innovative therapies for DMD, leveraging philanthropic donations to support research and development. By investing in early-stage companies, CureDuchenne Ventures aims to accelerate the availability of treatments for this devastating disease.

The firm's investment strategy includes providing both grant funding to academic groups and equity financing to biotech and pharmaceutical companies. This approach has led to significant advancements in DMD research, with several projects progressing to human clinical trials. Notably, CureDuchenne Ventures contributed early funding to Sarepta Therapeutics, facilitating the first FDA-approved drug for DMD.

CureDuchenne Ventures operates with a unique impact financing model, reinvesting proceeds from successful investments into further research and support for families affected by DMD. This model has attracted over $3 billion in follow-on financing from venture capital, biotech, and pharmaceutical companies, underscoring the firm's commitment to advancing DMD therapies and improving patient outcomes.